Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma.

Autor:	Smith-Cohn MA; Department of Neurology, University of Utah, Salt Lake City, 175 North Medical Drive East, UT 84132, USA., Gill D; Department of Hematology and Oncology, University of Utah School of Medicine, Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, UT 84112, USA., Voorhies BN; Department of Hematology and Oncology, University of Utah School of Medicine, Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, UT 84112, USA., Agarwal N; Department of Hematology and Oncology, University of Utah School of Medicine, Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, UT 84112, USA., Garrido-Laguna I; Department of Hematology and Oncology, University of Utah School of Medicine, Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, UT 84112, USA.
Jazyk:	angličtina
Zdroj:	Immunotherapy [Immunotherapy] 2017 Sep; Vol. 9 (10), pp. 797-804.
DOI:	10.2217/imt-2017-0042
Abstrakt:	Background: Immune checkpoint inhibitors are novel cancer therapies associated with numerous autoimmune toxicities, some of which are only now being appreciated. Case Presentation: A 67-year old female with metastatic cholangiocarcinoma and no prior history of diabetes was treated with leucovorin, fluorouracil, oxaliplatin and pembrolizumab. After eight cycles, she developed new onset type 1 diabetes mellitus with positive glutamic acid decarboxylase antibody titers. Conclusions: To our knowledge, this is the first reported case of PD-1 inhibitor associated Type 1 diabetes mellitus in a patient with cholangiocarcinoma and supports others' experiences that PD-1 inhibition can cause a spectrum of autoimmune adverse events that require clinical monitoring and periodic screenings.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu